SlideShare a Scribd company logo
1 of 2
Analysis of Caesarian Section rates in Gestational Diabetes using
the Robson Groups to allow meaningful examination of Data:
Important implications to clinical practice and patient counseling
W Courtney, C Carroll, Dr D Courtney, Dr M Higgins, Dr M Robson, ProfF McAuliffe, Pr of M Foley
Introduction
Figure 3 - Caesarean section rates in general populationand in women with GDM as per Robson groups
This study aimed to investigate the
rate of caesarean section (CS) in
gestational diabetes mellitus (GDM), as
classified by the Robson Criteria (1), a
commonly used method of analysis.
Methods
We designed a prospective study of
all women with GDMin a largetertiary
level unit. Cases were classified into
their relevant Robson group and
compared based on the rate of
caesarean section (CS).
GDM, though affecting a minority of
obstetric patients, is increasing in
numbers and traditionally infers a
high rate of maternal and fetal
morbidity and mortality.
Results
In a 7 year period, between 1 January
2005 and 31 December 2011, 61,116
women delivered infants at greater
Figure 3 demonstrates the Robson Ten Group
Caesarean Section delivery rates in the general
population vs. those who underwent caesarean
section with GDM.
This is further broken down in Table 1.
Table1: Robson Ten Group Caesarean Section Delivery rates
in Diet controlled GDM vs. Insulin Controlled GDM vs. General
Overall GDM CS Rate (%)
Overall CS Rate (%)
The majority of women with GDM, who had
had a previous CS, delivered by repeat CS
(71%).
Figure 4 – Nulliparous women undergoing
induction with and without GDM
80
than 24 weeks gestation in this unit; of
these 1126 (1.8%) were diagnosed with
gestational diabetes (Figure 1).
Figure 1 – Percentage ofwomen with and
without GDM
Population 60
40
20
0
Robson 2a Robson 4a
With GDM
Without
GDM
Women
without GDM
(98.2%)
Women with
GDM(1.8%)
During this time the overall hospital
CS rate was 19.6%, compared to a
32.5% rate in women with GDM.
(Figure2)
Figure 2
100%
90%
80%
70%
60%
50%
Conclusion
The incidence of GDM in this hospital
population remains low. Women with a
diagnosis of GDM had over 1.5 times
the risk of needing CS compared
to the general population.
Those women undergoing induction of
Labour(2aand4a)were more likely to need CS
than those who went into spontaneous
labour(SL).Those induced, that were
nulliparous(2a), were more than twice as
likely as their non- diabetic counterpartsto
need CS. This warrants further investigation:
when might it be more appropriate to avoid a
trial of labour in such women and perform
elective CS? How should we counsel such
women? Given that diet controlled GDM
patients had a higher rate of CS than insulin
controlled, particularly in group 2a, should
we consider the benefit of lowering the
threshold for commencing insulin therapy?
40%
30%
20%
10%
0%
Normal
births (%)
Caesarean
sections(%)
Nulliparous and multiparous women, undergoing
induction of labour (Groups 2a and 4a), had an
increased CS delivery rate (63% in nulliparous
women vs. 20% in multiparouswomen). (See Figure
4.)
Robson Group
Diet
GDM CS
Rate (%)
Insulin
GDM CS
Rate (%)
Overall
GDM CS
Rate
(%)
Overall Non- DM
CS Rate (%)
1
Nulliparous, single cephalic >37 weeks
in spontaneous labour
(28/159)
18.3
(13/65)
20
(41/218)
18.8
(1176/16421)
7.2
2 (23/29)
79.3
(18/34)
52.9
(41/63)
65.1
(2869/869)
33.6
2a
Nulliparous, single cephalic >37 weeks
in induced labour
(21/27)
77.8
(17/33)
51.52 (38/60)
63.33
(2323/8046)
28.87
2b
Nulliparous, single cephalic CS before
labour
(2/2) 100
(1/1)
100
(3/3)
100
(573/573)
100
3
Multiparous, single cephalic >37 weeks
in spontaneous labour
(2/282)
0.71
(0/109)
0 (2/ 391)
.51
(220/18321)
1.2
4
(17/45)
37.8
(11/43)
25.6
(28/ 88)
31.8
(765/6139)
12.5
4a
Multiparous, single cephalic >37 weeks
in induced labour
(8/36)
22.22
(7/39)
17.9 (15/75)
20
(312/5696)
5.5
4b
Multiparous, single cephalic >37 weeks
CS before labour
(9/9) 100
(4/4)
100 (13/13)
100
(443/443)
100
5
Previous CS, singlecephalic>37 weeks
(109/159
) 68.5
(78/102)
76.5
(187/261)
71.6
(3364/5735)
58.6
6
All nulliparous breeches
(7/7) 100
(6/6)
100
(13/13)
100
(1177/1273) 92.5
7
All multiparous breeches (incl. previous
CS)
(5/5) 100
(4/4)
100 (9/9)
100
(685/815) 84.1
8
All multiple pregnancies (incl. previous
CS)
(13/20)
65
(4/5) 80 (17/25)
68
(654/1066) 60.7
9
All abnormal lies (incl. previous CS)
(2/2) 100
(4/4)
100
(6/6)
100
(220/220)
100
10
All single, cephalic, <=36 weeks (incl.
previous CS)
(9/27) 33
(13/25)
52 (22/52)
37.9
(882/2546) 34.6
Total (%)
(215/72)
29.49
(151/37)
38.04
(366/112
6)
32.5
(12029/61166)
19.67
Reference
s
1.
Robs
on
MS.
Can
we
redu
ce
the
caes
area
n
secti
on
rate?
;
Best
Pract
ice &
Rese
arch
Clinic
al
Obst
etrics
&
Gyna
ecolo
gy.
2001
;15(1
):179
-94.

More Related Content

What's hot

Treating Pain and Neuropathy in Metastatic Breast Cancer
Treating Pain and Neuropathy in Metastatic Breast Cancer Treating Pain and Neuropathy in Metastatic Breast Cancer
Treating Pain and Neuropathy in Metastatic Breast Cancer Dana-Farber Cancer Institute
 
The B-AHEAD 2 Trial: Randomised controlled trial of intermittent versus conti...
The B-AHEAD 2 Trial: Randomised controlled trial of intermittent versus conti...The B-AHEAD 2 Trial: Randomised controlled trial of intermittent versus conti...
The B-AHEAD 2 Trial: Randomised controlled trial of intermittent versus conti...World Cancer Research Fund International
 
8. Brest Cancer - hindu female-2014
8. Brest Cancer - hindu female-20148. Brest Cancer - hindu female-2014
8. Brest Cancer - hindu female-2014Pulakes Purkait
 
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...Dana-Farber Cancer Institute
 
Genetic testing of breast and ovarian cancer patients: clinical characteristi...
Genetic testing of breast and ovarian cancer patients: clinical characteristi...Genetic testing of breast and ovarian cancer patients: clinical characteristi...
Genetic testing of breast and ovarian cancer patients: clinical characteristi...dewisetiyana52
 
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...Emad Shash
 
Dr Ayman Ewies - Prevalence of hyperplasia and cancer in endometrial polyps i...
Dr Ayman Ewies - Prevalence of hyperplasia and cancer in endometrial polyps i...Dr Ayman Ewies - Prevalence of hyperplasia and cancer in endometrial polyps i...
Dr Ayman Ewies - Prevalence of hyperplasia and cancer in endometrial polyps i...AymanEwies
 
New Treatment Options for Uterine Cancer
New Treatment Options for Uterine CancerNew Treatment Options for Uterine Cancer
New Treatment Options for Uterine Cancerbkling
 
The diagnostic outcome for women presenting with postcoital bleeding - Dr Aym...
The diagnostic outcome for women presenting with postcoital bleeding - Dr Aym...The diagnostic outcome for women presenting with postcoital bleeding - Dr Aym...
The diagnostic outcome for women presenting with postcoital bleeding - Dr Aym...AymanEwies
 
Genomics and Metastatic Breast Cancer: Where Are We Today?
Genomics and Metastatic Breast Cancer: Where Are We Today?Genomics and Metastatic Breast Cancer: Where Are We Today?
Genomics and Metastatic Breast Cancer: Where Are We Today?Dana-Farber Cancer Institute
 
Report Back from ASCO on Metastatic Breast Cancer
Report Back from ASCO on Metastatic Breast CancerReport Back from ASCO on Metastatic Breast Cancer
Report Back from ASCO on Metastatic Breast Cancerbkling
 
Study the role of estradiol and luteinizing hormones in breast tumors inciden...
Study the role of estradiol and luteinizing hormones in breast tumors inciden...Study the role of estradiol and luteinizing hormones in breast tumors inciden...
Study the role of estradiol and luteinizing hormones in breast tumors inciden...Alexander Decker
 
Living with Advanced Breast Cancer: Challenges and Opportunities
Living with Advanced Breast Cancer: Challenges and OpportunitiesLiving with Advanced Breast Cancer: Challenges and Opportunities
Living with Advanced Breast Cancer: Challenges and Opportunitiesbkling
 
Association between variations in the fat mass and obesity-associated gene an...
Association between variations in the fat mass and obesity-associated gene an...Association between variations in the fat mass and obesity-associated gene an...
Association between variations in the fat mass and obesity-associated gene an...Enrique Moreno Gonzalez
 
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
The Changing Role of PARP Inhibitors in the Treatment of Ovarian CancerThe Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancerbkling
 
What's New in Research for ER+ Metastatic Breast Cancer
What's New in Research for ER+ Metastatic Breast CancerWhat's New in Research for ER+ Metastatic Breast Cancer
What's New in Research for ER+ Metastatic Breast CancerDana-Farber Cancer Institute
 

What's hot (20)

Treating Pain and Neuropathy in Metastatic Breast Cancer
Treating Pain and Neuropathy in Metastatic Breast Cancer Treating Pain and Neuropathy in Metastatic Breast Cancer
Treating Pain and Neuropathy in Metastatic Breast Cancer
 
The B-AHEAD 2 Trial: Randomised controlled trial of intermittent versus conti...
The B-AHEAD 2 Trial: Randomised controlled trial of intermittent versus conti...The B-AHEAD 2 Trial: Randomised controlled trial of intermittent versus conti...
The B-AHEAD 2 Trial: Randomised controlled trial of intermittent versus conti...
 
8. Brest Cancer - hindu female-2014
8. Brest Cancer - hindu female-20148. Brest Cancer - hindu female-2014
8. Brest Cancer - hindu female-2014
 
Healthy Living After A Breast Cancer Diagnosis
Healthy Living After A Breast Cancer DiagnosisHealthy Living After A Breast Cancer Diagnosis
Healthy Living After A Breast Cancer Diagnosis
 
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
Making Progress in the Treatment of Estrogen Receptor Positive Metastatic Bre...
 
Genetic testing of breast and ovarian cancer patients: clinical characteristi...
Genetic testing of breast and ovarian cancer patients: clinical characteristi...Genetic testing of breast and ovarian cancer patients: clinical characteristi...
Genetic testing of breast and ovarian cancer patients: clinical characteristi...
 
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
Impact of Multidisciplinary Discussion on Treatment Outcome For Gynecologic C...
 
Dr Ayman Ewies - Prevalence of hyperplasia and cancer in endometrial polyps i...
Dr Ayman Ewies - Prevalence of hyperplasia and cancer in endometrial polyps i...Dr Ayman Ewies - Prevalence of hyperplasia and cancer in endometrial polyps i...
Dr Ayman Ewies - Prevalence of hyperplasia and cancer in endometrial polyps i...
 
New Treatment Options for Uterine Cancer
New Treatment Options for Uterine CancerNew Treatment Options for Uterine Cancer
New Treatment Options for Uterine Cancer
 
The diagnostic outcome for women presenting with postcoital bleeding - Dr Aym...
The diagnostic outcome for women presenting with postcoital bleeding - Dr Aym...The diagnostic outcome for women presenting with postcoital bleeding - Dr Aym...
The diagnostic outcome for women presenting with postcoital bleeding - Dr Aym...
 
Genomics and Metastatic Breast Cancer: Where Are We Today?
Genomics and Metastatic Breast Cancer: Where Are We Today?Genomics and Metastatic Breast Cancer: Where Are We Today?
Genomics and Metastatic Breast Cancer: Where Are We Today?
 
Report Back from ASCO on Metastatic Breast Cancer
Report Back from ASCO on Metastatic Breast CancerReport Back from ASCO on Metastatic Breast Cancer
Report Back from ASCO on Metastatic Breast Cancer
 
What’s New With HER2?
What’s New With HER2?What’s New With HER2?
What’s New With HER2?
 
August 2019 - Recurrence: What now?
August 2019 - Recurrence: What now?August 2019 - Recurrence: What now?
August 2019 - Recurrence: What now?
 
Study the role of estradiol and luteinizing hormones in breast tumors inciden...
Study the role of estradiol and luteinizing hormones in breast tumors inciden...Study the role of estradiol and luteinizing hormones in breast tumors inciden...
Study the role of estradiol and luteinizing hormones in breast tumors inciden...
 
Living with Advanced Breast Cancer: Challenges and Opportunities
Living with Advanced Breast Cancer: Challenges and OpportunitiesLiving with Advanced Breast Cancer: Challenges and Opportunities
Living with Advanced Breast Cancer: Challenges and Opportunities
 
Research Day Poster
Research Day PosterResearch Day Poster
Research Day Poster
 
Association between variations in the fat mass and obesity-associated gene an...
Association between variations in the fat mass and obesity-associated gene an...Association between variations in the fat mass and obesity-associated gene an...
Association between variations in the fat mass and obesity-associated gene an...
 
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
The Changing Role of PARP Inhibitors in the Treatment of Ovarian CancerThe Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
The Changing Role of PARP Inhibitors in the Treatment of Ovarian Cancer
 
What's New in Research for ER+ Metastatic Breast Cancer
What's New in Research for ER+ Metastatic Breast CancerWhat's New in Research for ER+ Metastatic Breast Cancer
What's New in Research for ER+ Metastatic Breast Cancer
 

Viewers also liked

карта мышления
карта мышлениякарта мышления
карта мышленияkirovaevgenia
 
Managing health reform through an economic downturn
Managing health reform through an economic downturnManaging health reform through an economic downturn
Managing health reform through an economic downturnNuffield Trust
 
карта мышления
карта мышлениякарта мышления
карта мышленияkirovaevgenia
 
Nagaraja Naik - Resume 105805
Nagaraja Naik - Resume 105805Nagaraja Naik - Resume 105805
Nagaraja Naik - Resume 105805Nagaraja Naik
 
Peter Morrison Resume Sept 2015
Peter Morrison Resume Sept 2015Peter Morrison Resume Sept 2015
Peter Morrison Resume Sept 2015Peter Morrison
 
Onderwijstijd: neem de ruimte!
Onderwijstijd: neem de ruimte!Onderwijstijd: neem de ruimte!
Onderwijstijd: neem de ruimte!servicepuntihks
 
Examens voor keuzedelen: kip of ei?
Examens voor keuzedelen: kip of ei?Examens voor keuzedelen: kip of ei?
Examens voor keuzedelen: kip of ei?servicepuntihks
 
Mamma mia proabastos
Mamma mia proabastosMamma mia proabastos
Mamma mia proabastosreina
 

Viewers also liked (8)

карта мышления
карта мышлениякарта мышления
карта мышления
 
Managing health reform through an economic downturn
Managing health reform through an economic downturnManaging health reform through an economic downturn
Managing health reform through an economic downturn
 
карта мышления
карта мышлениякарта мышления
карта мышления
 
Nagaraja Naik - Resume 105805
Nagaraja Naik - Resume 105805Nagaraja Naik - Resume 105805
Nagaraja Naik - Resume 105805
 
Peter Morrison Resume Sept 2015
Peter Morrison Resume Sept 2015Peter Morrison Resume Sept 2015
Peter Morrison Resume Sept 2015
 
Onderwijstijd: neem de ruimte!
Onderwijstijd: neem de ruimte!Onderwijstijd: neem de ruimte!
Onderwijstijd: neem de ruimte!
 
Examens voor keuzedelen: kip of ei?
Examens voor keuzedelen: kip of ei?Examens voor keuzedelen: kip of ei?
Examens voor keuzedelen: kip of ei?
 
Mamma mia proabastos
Mamma mia proabastosMamma mia proabastos
Mamma mia proabastos
 

Similar to Poster William

BREAST CANCER AND SOME EPIDEMIOLOGICAL FACTORS:
BREAST CANCER AND SOME EPIDEMIOLOGICAL FACTORS:BREAST CANCER AND SOME EPIDEMIOLOGICAL FACTORS:
BREAST CANCER AND SOME EPIDEMIOLOGICAL FACTORS:Mario Guillermo Simonovich
 
What is the status of surgical interventions for infertility in patients of p...
What is the status of surgical interventions for infertility in patients of p...What is the status of surgical interventions for infertility in patients of p...
What is the status of surgical interventions for infertility in patients of p...Apollo Hospitals
 
Effect of three decades of screening mammography on breast cancer incidence
Effect of three decades of screening mammography on breast cancer incidenceEffect of three decades of screening mammography on breast cancer incidence
Effect of three decades of screening mammography on breast cancer incidenceDave Chase
 
Management of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivorsManagement of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivorsTevfik Yoldemir
 
Tackling Obesity in Infertility
Tackling Obesity in InfertilityTackling Obesity in Infertility
Tackling Obesity in InfertilitySujoy Dasgupta
 
ueda2012 diabetes and pregnancy-dmgahed
ueda2012 diabetes and pregnancy-dmgahedueda2012 diabetes and pregnancy-dmgahed
ueda2012 diabetes and pregnancy-dmgahedueda2015
 
Knowledge Discovery from Breast Cancer Database
Knowledge Discovery from Breast Cancer DatabaseKnowledge Discovery from Breast Cancer Database
Knowledge Discovery from Breast Cancer Databaseiosrjce
 
SAMPLE SIZE PG 2-2.pdf
SAMPLE SIZE PG 2-2.pdfSAMPLE SIZE PG 2-2.pdf
SAMPLE SIZE PG 2-2.pdfssuser82d3bb
 
On Gestational Diabetes By Final Year Students Of Kmdc
On Gestational Diabetes By Final Year Students Of KmdcOn Gestational Diabetes By Final Year Students Of Kmdc
On Gestational Diabetes By Final Year Students Of KmdcZia Khan
 
Crimson Publishers-Knowledge of Obesity Risks and Women’s Health: What do we ...
Crimson Publishers-Knowledge of Obesity Risks and Women’s Health: What do we ...Crimson Publishers-Knowledge of Obesity Risks and Women’s Health: What do we ...
Crimson Publishers-Knowledge of Obesity Risks and Women’s Health: What do we ...Crimsonpublishers-IGRWH
 
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives Graham Colditz
 
Normal and abnormal delivery Dr Falakha
Normal and abnormal delivery Dr FalakhaNormal and abnormal delivery Dr Falakha
Normal and abnormal delivery Dr Falakhagfalakha
 
Breastfeeding & bariatric surgery / Amamentação em nutrizes submetidas à ciru...
Breastfeeding & bariatric surgery / Amamentação em nutrizes submetidas à ciru...Breastfeeding & bariatric surgery / Amamentação em nutrizes submetidas à ciru...
Breastfeeding & bariatric surgery / Amamentação em nutrizes submetidas à ciru...Prof. Marcus Renato de Carvalho
 

Similar to Poster William (20)

Cancer in pregnancy
Cancer in pregnancyCancer in pregnancy
Cancer in pregnancy
 
BREAST CANCER AND SOME EPIDEMIOLOGICAL FACTORS:
BREAST CANCER AND SOME EPIDEMIOLOGICAL FACTORS:BREAST CANCER AND SOME EPIDEMIOLOGICAL FACTORS:
BREAST CANCER AND SOME EPIDEMIOLOGICAL FACTORS:
 
What is the status of surgical interventions for infertility in patients of p...
What is the status of surgical interventions for infertility in patients of p...What is the status of surgical interventions for infertility in patients of p...
What is the status of surgical interventions for infertility in patients of p...
 
Diabetes in Pregnancy Gestational Diabetes - Idea Clinics | Institute of Diab...
Diabetes in Pregnancy Gestational Diabetes - Idea Clinics | Institute of Diab...Diabetes in Pregnancy Gestational Diabetes - Idea Clinics | Institute of Diab...
Diabetes in Pregnancy Gestational Diabetes - Idea Clinics | Institute of Diab...
 
Effect of three decades of screening mammography on breast cancer incidence
Effect of three decades of screening mammography on breast cancer incidenceEffect of three decades of screening mammography on breast cancer incidence
Effect of three decades of screening mammography on breast cancer incidence
 
Laparoscopy 1
Laparoscopy  1Laparoscopy  1
Laparoscopy 1
 
Management of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivorsManagement of menopausal symptoms for breast cancer survivors
Management of menopausal symptoms for breast cancer survivors
 
Tackling Obesity in Infertility
Tackling Obesity in InfertilityTackling Obesity in Infertility
Tackling Obesity in Infertility
 
Type 2 Diabetes and Cancer
Type 2 Diabetes and CancerType 2 Diabetes and Cancer
Type 2 Diabetes and Cancer
 
ueda2012 diabetes and pregnancy-dmgahed
ueda2012 diabetes and pregnancy-dmgahedueda2012 diabetes and pregnancy-dmgahed
ueda2012 diabetes and pregnancy-dmgahed
 
Knowledge Discovery from Breast Cancer Database
Knowledge Discovery from Breast Cancer DatabaseKnowledge Discovery from Breast Cancer Database
Knowledge Discovery from Breast Cancer Database
 
SAMPLE SIZE PG 2-2.pdf
SAMPLE SIZE PG 2-2.pdfSAMPLE SIZE PG 2-2.pdf
SAMPLE SIZE PG 2-2.pdf
 
Communicating risk
Communicating riskCommunicating risk
Communicating risk
 
On Gestational Diabetes By Final Year Students Of Kmdc
On Gestational Diabetes By Final Year Students Of KmdcOn Gestational Diabetes By Final Year Students Of Kmdc
On Gestational Diabetes By Final Year Students Of Kmdc
 
Crimson Publishers-Knowledge of Obesity Risks and Women’s Health: What do we ...
Crimson Publishers-Knowledge of Obesity Risks and Women’s Health: What do we ...Crimson Publishers-Knowledge of Obesity Risks and Women’s Health: What do we ...
Crimson Publishers-Knowledge of Obesity Risks and Women’s Health: What do we ...
 
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
Diet, obesity, lifestyle and cancer prevention: epidemiologic perspectives
 
Normal and abnormal delivery Dr Falakha
Normal and abnormal delivery Dr FalakhaNormal and abnormal delivery Dr Falakha
Normal and abnormal delivery Dr Falakha
 
Canadian cx cancer 2012
Canadian cx cancer 2012Canadian cx cancer 2012
Canadian cx cancer 2012
 
Gestational diabetes mellitus
Gestational diabetes mellitusGestational diabetes mellitus
Gestational diabetes mellitus
 
Breastfeeding & bariatric surgery / Amamentação em nutrizes submetidas à ciru...
Breastfeeding & bariatric surgery / Amamentação em nutrizes submetidas à ciru...Breastfeeding & bariatric surgery / Amamentação em nutrizes submetidas à ciru...
Breastfeeding & bariatric surgery / Amamentação em nutrizes submetidas à ciru...
 

Poster William

  • 1. Analysis of Caesarian Section rates in Gestational Diabetes using the Robson Groups to allow meaningful examination of Data: Important implications to clinical practice and patient counseling W Courtney, C Carroll, Dr D Courtney, Dr M Higgins, Dr M Robson, ProfF McAuliffe, Pr of M Foley Introduction Figure 3 - Caesarean section rates in general populationand in women with GDM as per Robson groups This study aimed to investigate the rate of caesarean section (CS) in gestational diabetes mellitus (GDM), as classified by the Robson Criteria (1), a commonly used method of analysis. Methods We designed a prospective study of all women with GDMin a largetertiary level unit. Cases were classified into their relevant Robson group and compared based on the rate of caesarean section (CS). GDM, though affecting a minority of obstetric patients, is increasing in numbers and traditionally infers a high rate of maternal and fetal morbidity and mortality. Results In a 7 year period, between 1 January 2005 and 31 December 2011, 61,116 women delivered infants at greater Figure 3 demonstrates the Robson Ten Group Caesarean Section delivery rates in the general population vs. those who underwent caesarean section with GDM. This is further broken down in Table 1. Table1: Robson Ten Group Caesarean Section Delivery rates in Diet controlled GDM vs. Insulin Controlled GDM vs. General Overall GDM CS Rate (%) Overall CS Rate (%) The majority of women with GDM, who had had a previous CS, delivered by repeat CS (71%). Figure 4 – Nulliparous women undergoing induction with and without GDM 80 than 24 weeks gestation in this unit; of these 1126 (1.8%) were diagnosed with gestational diabetes (Figure 1). Figure 1 – Percentage ofwomen with and without GDM Population 60 40 20 0 Robson 2a Robson 4a With GDM Without GDM Women without GDM (98.2%) Women with GDM(1.8%) During this time the overall hospital CS rate was 19.6%, compared to a 32.5% rate in women with GDM. (Figure2) Figure 2 100% 90% 80% 70% 60% 50% Conclusion The incidence of GDM in this hospital population remains low. Women with a diagnosis of GDM had over 1.5 times the risk of needing CS compared to the general population. Those women undergoing induction of Labour(2aand4a)were more likely to need CS than those who went into spontaneous labour(SL).Those induced, that were nulliparous(2a), were more than twice as likely as their non- diabetic counterpartsto need CS. This warrants further investigation: when might it be more appropriate to avoid a trial of labour in such women and perform elective CS? How should we counsel such women? Given that diet controlled GDM patients had a higher rate of CS than insulin controlled, particularly in group 2a, should we consider the benefit of lowering the threshold for commencing insulin therapy? 40% 30% 20% 10% 0% Normal births (%) Caesarean sections(%) Nulliparous and multiparous women, undergoing induction of labour (Groups 2a and 4a), had an increased CS delivery rate (63% in nulliparous women vs. 20% in multiparouswomen). (See Figure 4.) Robson Group Diet GDM CS Rate (%) Insulin GDM CS Rate (%) Overall GDM CS Rate (%) Overall Non- DM CS Rate (%) 1 Nulliparous, single cephalic >37 weeks in spontaneous labour (28/159) 18.3 (13/65) 20 (41/218) 18.8 (1176/16421) 7.2 2 (23/29) 79.3 (18/34) 52.9 (41/63) 65.1 (2869/869) 33.6 2a Nulliparous, single cephalic >37 weeks in induced labour (21/27) 77.8 (17/33) 51.52 (38/60) 63.33 (2323/8046) 28.87 2b Nulliparous, single cephalic CS before labour (2/2) 100 (1/1) 100 (3/3) 100 (573/573) 100 3 Multiparous, single cephalic >37 weeks in spontaneous labour (2/282) 0.71 (0/109) 0 (2/ 391) .51 (220/18321) 1.2 4 (17/45) 37.8 (11/43) 25.6 (28/ 88) 31.8 (765/6139) 12.5 4a Multiparous, single cephalic >37 weeks in induced labour (8/36) 22.22 (7/39) 17.9 (15/75) 20 (312/5696) 5.5 4b Multiparous, single cephalic >37 weeks CS before labour (9/9) 100 (4/4) 100 (13/13) 100 (443/443) 100 5 Previous CS, singlecephalic>37 weeks (109/159 ) 68.5 (78/102) 76.5 (187/261) 71.6 (3364/5735) 58.6 6 All nulliparous breeches (7/7) 100 (6/6) 100 (13/13) 100 (1177/1273) 92.5 7 All multiparous breeches (incl. previous CS) (5/5) 100 (4/4) 100 (9/9) 100 (685/815) 84.1 8 All multiple pregnancies (incl. previous CS) (13/20) 65 (4/5) 80 (17/25) 68 (654/1066) 60.7 9 All abnormal lies (incl. previous CS) (2/2) 100 (4/4) 100 (6/6) 100 (220/220) 100 10 All single, cephalic, <=36 weeks (incl. previous CS) (9/27) 33 (13/25) 52 (22/52) 37.9 (882/2546) 34.6 Total (%) (215/72) 29.49 (151/37) 38.04 (366/112 6) 32.5 (12029/61166) 19.67